Report Highlights
The global systemic antibiotics market was valued at $39.6 billion in 2013 and is expected to reach $41.2 billion by 2018, at a CAGR of 0.8%.
Report Includes
- An overview of the global market for systemic antibiotics.
- Analyses of global market trends, with data from 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Details on the factors most impacting the market, including major market growth inhibitors and catalysts.
- Discussion on important trends and products.
- Comprehensive profiles of leading companies in the industry.
SCOPE OF REPORT
This research report categorizes the systemic antibiotics market into the following segments:
Antibiotics market (human application) by product:
- Beta-lactams.
- Penicillin.
- Cephalosporins.
- Carbapenems.
- Fluoroquinolones.
- Second generation.
- Third generation.
- Others.
- Macrolides.
- Tetracycline.
- Other antibiotic classes.
Antibiotics market by application:
- Human applications.
- Veterinary applications.
ANALYST CREDENTIALS
Neha Maliwal, a graduate in biotechnology and a postgraduate in marketing and biotechnology from the University of Pune (India), is the author this study and numerous others, including the analyses of related markets such as radiopharmaceuticals, healthcare business process outsourcing (BPO) and biotechnology instrumentation.
A special mention goes to Silva Quattrocchi, who has a master’s degree in molecular biotechnology from the University of Bologna (Italy), for her input on the antibiotics market.
Report Highlights
- Overall sales in the current antibiotics and new products market were nearly $40 billion in 2008. It increased to $41.5 billion in 2009. By 2014, it is projected to increase to $65.5 billion, for a 5-year compound annual growth rate (CAGR) of 9.6%.
- The largest segment antibiotic drugs market was nearly $36 billion in 2008; this further increased to $37 billion in 2009, this projected to reach $50 billion in 2014, for a 5-year CAGR of 5.9%.
- Sales in the bacterial vaccines market amounted to $3.6 billion in 2008 which increased slightly to $3.9 billion in 2009. This is projected to increase to $15 billion in 2014, for a 5-year CAGR of 31.6%.
Report Highlights
- Worldwide, the total market for new and currently available antibiotics reached $22.3 billion in 2001. Average annual growth rate (AAGR) of 9.1%, this market will climb to $34.5 billion in 2006.
- Growth will be driven by new products, whose sales will rise at an AAGR of more than 50% to $7.4 billion in 2006, representing 21% of the total market.
- Sales in 2001 were just under $1 billion, just 4% of the market.
- In 2001, the market for currently available antibiotics was $21.3 billion and is projected to increase at an AAGR of only 4.9% to $27.2 billion by 2006.
- From 2001 to 2006, some 40 new products or formulations could be introduced into the antibiotics sector.
- Many of these drugs will likely prove effective against infectious disease organisms that have developed multidrug resistances, rejuvenating the antibiotics market.
Related Reports
Global Markets and Technologies for Pandemic Control
The total market for pandemic infectious disease products broken down by disease type was $31.6 billion in 2011 and $35.6 billion in 2012. The market is expected to rise at a CAGR of 9.3% and reach nearly $55.6 billion by 2017.
Antifungal Drugs: Technologies and Global Markets
The global market for antifungal therapeutics was valued at $10.7 billion in 2011 and is projected to reach $12.2 billion in 2016, a five-year compound annual growth rate (CAGR) of 2.7%.
The Global Compound Feed Market: Technology Developments and Market Changes
The global market value of feed additives products was $16.1 billion in 2010 and is expected to grow to $27.6 billion in 2017 at an estimated compound annual growth rate (CAGR) of 8.1% from 2010 to 2017.
Recent Reports
Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets
The global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.
Rare Disease Diagnostics: Technologies and Global Markets
The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.
Breakthrough Therapies: Market Dynamics and Investment Opportunities
The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.
Softgel Capsules: Global Markets
The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More